In the trastuzumab for gastric cancer (ToGA) trial, the overall survival (OS) of patients with HER2-positive advanced gastric cancer was improved 2.7 months when trastuzumab was combined with conventional chemotherapy, compared to chemotherapy alone. Here, ERBB2 is linked to gastric cancer.